Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model

Biochemistry, Genetics and Molecular Biology

• GD2 100%
• Mouse 80%
• Antibody 60%
• Stem Cell 50%
• Syngenic 40%
• Mouse Model 30%
• Homing Behavior 30%
• Natural Killer Cell 20%
• Development 10%
• Protein 10%
• Growth Rate 10%
• Immunostaining 10%
• Transgenic Mouse 10%
• Cancer Immunotherapy 10%
• Single-Chain Variable Fragment 10%
• Cell Infiltration 10%
• Growth Inhibition 10%

Medicine and Dentistry

• Antibody 60%
• Neoplasm 50%
• Mesenchymal Stem Cell 50%
• Ganglioneuroblastoma 30%
• Natural Killer Cell 20%
• Development 10%
• Combination Therapy 10%
• Tissues 10%
• Tumor Invasion 10%
• Immunohistochemistry 10%
• Protein 10%
• Transplantation 10%
• Transgenic Mouse 10%
• Tumor Progression 10%
• Injection 10%
• Growth Rate 10%
• Immunotherapy 10%
• Single Chain Fragment Variable Antibody 10%
• Cellular Infiltration 10%
• Cancer Immunotherapy 10%
• Growth Inhibition 10%